Josep Tabernero, MD, PhD

MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)

BackgroundMONEO was an open-label, non-randomized, multicentric, phase II study that explored the combination of the anti-PD-1 antibody avelumab (Av) plus peri-operative FLOT (docetaxel, ...

A. Lopez-Janeiro ;

P. Jimenez-Fonseca ;

V. Arrazubi ;

M. Diez Garcia ;

E. Sanz-Garcia ;

E. Martinez de Castro ;

R. Guardeno Sanchez ;

M. Calvo Campos ;

C. Buges Sanchez ;

F. Longo ;

M. Alsina ;

V. Navarro ;

M. Ponz-Sarvise ;

A. Gros ;

D. Lopez Garcia ;

A. Vivancos ;

G. Villacampa ;

Josep Tabernero , MD, PhD;

C. De Andrea ;

S. Munoz ;

C. Ochoa ;

I. Melero ;

06/25/2023

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;

M. Valladares-Ayerbes ;

J. Vieitez de Prado ;

C. Gravalos ;

P. Garcia Alfonso ;

C. Santos ;

M. Tobena ;

J. Sastre ;

M. Benavides ;

07/01/2019

Zanzalintinib (XL092) in combination with atezolizumab for previously treated metastatic colorectal cancer

BackgroundMetastatic colorectal cancer (mCRC) is associated with poor prognosis, and patients who have progressed on first- and second-line chemotherapy have limited treatment options. Re...

Josep Tabernero , MD, PhD;

06/25/2023

Keynote Lecture: Coping with escalating healthcare costs in 2018 and beyond

Josep Tabernero , MD, PhD;

07/10/2018

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

BRAF mutations occur in 8% to 12% of patients with mCRC and are associated with clinically poor prognosis. E+C was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/25/2023

Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS

Introduction In the Phase III RECOURSE study, patients with metastatic colorectal cancer (mCRC) refractory to standard therapies demonstrated significantly extended overall survival and ...

Eric Van Cutsem , MD, PhD;

Alberto F. Sobrero , MD;

A. Ohtsu ;

Josep Tabernero , MD, PhD;

G. Argiles ;

R. Mayer ;

L. Vidot ;

S. Vera Moreno ;

07/01/2019

Precision Medicine Development in GI Oncology: Evidence-Based Guidelines Using Liquid Biopsies in Treatment, Decision Making, Optimizing Management, and Sequencing

Pierre Laurent-Puig , MD, PhD;

Clara Montagut , MD, PhD;

Josep Tabernero , MD, PhD;

07/07/2023

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

    KEYNOTE062 (NCT02494583) was a randomized, active controlled study of first-line (1L) pembrolizumab (P) or pembrolizumab plus chemotherapy (P+C) vs chemotherapy (C) in pts...

Charles S. Fuchs ;

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

07/01/2019

How to Make MSS Tumors More Sensitive for Immunotherapy?

Josep Tabernero , MD, PhD;

07/07/2023

KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Background KRAS G12C mutation occurs in 3-4% of colorectal cancer (CRC) and is associated with poor prognosis. KRAS is a key mediator of the RAS/MAPK signaling cascade a...

Josep Tabernero , MD, PhD;

06/28/2021